Surface Oncology Inc SURF:NASDAQ

Last Price$3.72NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$3.71 (2)
Ask (Size)$3.85 (1)
Day Low / HighN/A - N/A
Volume662.0 K

View Biotechnology IndustryPeer Comparison as of 01/21/2022


Surface Oncology Inc ( NASDAQ )

Price: $3.72
Change: -0.21 (5.34%)
Volume: 662.0 K
4:00PM ET 1/21/2022

ZIOPHARM Oncology Inc ( NASDAQ )

Price: $0.82
Change: -0.04 (5.11%)
Volume: 2.0 M
4:00PM ET 1/21/2022

Harpoon Therapeutics Inc ( NASDAQ )

Price: $5.09
Change: -0.08 (1.55%)
Volume: 228.5 K
4:00PM ET 1/21/2022

Molecular Templates Inc ( NASDAQ )

Price: $3.14
Change: -0.12 (3.68%)
Volume: 176.9 K
4:00PM ET 1/21/2022

Matinas BioPharma Holdings Inc ( NYSE MKT LLC )

Price: $0.82
Change: -0.03 (3.62%)
Volume: 1.4 M
6:30PM ET 1/21/2022

Read more news Recent News

Surface Oncology Names Denice Torres as Chair of Board of Directors
7:43AM ET 12/15/2021 MT Newswires

Surface Oncology (SURF) said Wednesday it appointed Denice Torres as chair of the board of directors. Torres has been a board member of the company since...

Surface Oncology Gets US FDA Clearance for Human Clinical Trial of Potential Anti-Tumor Therapy
8:39AM ET 12/01/2021 MT Newswires

Surface Oncology (SURF) said Wednesday the US Food and Drug Administration has cleared the company's investigational new drug application for its...

-- Earnings Flash (SURF) SURFACE ONCOLOGY Posts Q3 Revenue $392,000
7:18AM ET 11/04/2021 MT Newswires


Surface Oncology to Study Potential Antibody's Use For Treatment-Naive Hepatocellular Carcinoma
8:55AM ET 10/04/2021 MT Newswires

Surface Oncology (SURF) on Monday announced plans to start a randomized Phase 2 clinical study evaluating its SRF388 potential antibody against IL-27 in...

View all Commentary and Analysis

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
8:00AM ET 1/18/2022 Seeking Alpha

Surface Oncology: Staying The Course
7:44PM ET 10/24/2021 Seeking Alpha

Surface Oncology (SURF) Investor Presentation - Slideshow
4:30PM ET 8/13/2021 Seeking Alpha

Surface Oncology: A Diverse, But Early Pipeline
9:20PM ET 7/12/2021 Seeking Alpha

Company Profile

Business DescriptionSurface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also include licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. View company web site for more details
Address50 Hampshire Street
Cambridge, Massachusetts 02139
Number of Employees76
Recent SEC Filing01/14/20224
President, Chief Executive Officer & DirectorRobert W. Ross
Chief Financial OfficerJessica Fees
Chief Scientific OfficerVito J. Palombella
Chief Medical OfficerAlison M. O'Neill

Company Highlights

Price Open$3.98
Previous Close$3.93
52 Week Range$3.71 - 13.90
Market Capitalization$171.6 M
Shares Outstanding46.1 M
SectorHealth Technology
Next Earnings Announcement03/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings12.00
Earnings per Share$0.31
Beta vs. S&P 500N/A
Revenue$59.4 M
Net Profit Margin14.33%
Return on Equity8.69%

Analyst Ratings as of 05/14/2021

Consensus RecommendationConsensus Icon
Powered by Factset